A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)
Status:
Active, not recruiting
Trial end date:
2022-04-26
Target enrollment:
Participant gender:
Summary
This Phase IV, multicenter, single-arm, open-label study will evaluate the efficacy and
safety of tocilizumab in Chinese participants with sJIA with persistent activity and an
inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs) and steroid therapy.